DENTSPLY SIRONA (XRAY) AI Stock Analysis

• Market Cap: $3.17B
• Dividend Yield: 4.03%
• Average Volume (3M): 2.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -5.61%
• EPS Growth: -921.99%
• Country: US
• Employees: 14,000
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.43
• Shares Outstanding: 199,293,380
• 10 Day Avg. Volume: 2,322,838
• 30 Day Avg. Volume: 2,918,696
• PEG Ratio: 0.03
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.21
• Enterprise Value/Market Cap: 1.63
• Enterprise Value/Revenue: 0.33
• Enterprise Value/Gross Profit: 2.63
• Enterprise Value/Ebitda: 26.01
• 1Y Price Target: $17.55
• Price Target Upside: 10.10% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12

• Rating: 58 Neutral
• Price Target: $16.50 ▲(3.51%Upside)

DENTSPLY SIRONA's overall stock score reflects significant financial performance challenges, with declining revenues and negative margins impacting the score. Technical analysis suggests some stabilization, while the earnings call highlighted both operational strengths and market challenges. Valuation remains a concern with a negative P/E ratio, although the dividend yield is a positive factor for some investors.

Positive Factors

Cost Management

Cost control and margin expansion was the most impressive element of the 1Q print.

Financial Performance

Dentsply Sirona generated $879 million in net sales versus the estimate of $863 million, exceeding expectations.

Management Stability

The appointment of a permanent CFO is an incremental positive for XRAY as it solidifies the management team and paves the way for effective execution of the company’s strategic initiatives.

Negative Factors

Management Uncertainty

The focus on the call will be details on the unexpected and abrupt departure of its Interim CFO, calling into question the latest guidance.

Market Conditions

There remains a lot to work through in terms of the reinvigoration key areas of XRAY's portfolio in the backdrop of a choppy operating environment.

Sales Decline

Reported sales were down 7.7% versus the same period last year.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA, Inc. is a leading global manufacturer and distributor of dental products and technologies. The company operates in the healthcare sector, specifically focusing on dental solutions. Its core products and services include dental equipment, dental consumables, and dental specialty products. DENTSPLY SIRONA serves dental professionals worldwide, offering innovative solutions to enhance dental practice efficiency and patient care.

How the Company Makes Money

DENTSPLY SIRONA generates revenue primarily through the sale of its dental products and technologies. This includes a wide range of dental equipment such as imaging systems, treatment centers, and instruments, as well as consumables like dental implants, orthodontic products, and restorative materials. The company also earns from providing repair and maintenance services for its equipment. Key revenue streams include direct sales to dental professionals and partnerships with dental distributors globally. Strategic alliances and collaborations with dental associations and educational institutions further enhance its market reach and contribute to its revenue.

DENTSPLY SIRONA Financial Statement Overview

Summary

DENTSPLY SIRONA has faced challenges with declining revenue and profitability, as reflected in the income statement. The balance sheet shows increased leverage, posing potential financial risks. While the cash flow statement indicates some resilience in cash generation, continued negative income could threaten long-term stability. Financial pressures demand strategic actions.

Income Statement

DENTSPLY SIRONA has experienced significant revenue decline over the past years, with a decrease from $4.25 billion in 2021 to $3.79 billion in 2024. The company also shows a negative net income of $910 million in 2024, with net profit margins consistently negative. Although the gross profit margin remains relatively stable, EBIT and EBITDA margins have deteriorated, indicating challenges in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has increased over the years, indicating higher leverage and potential financial risk. Stockholders' equity has decreased significantly, impacting the equity ratio. Despite this, the company's total assets remain robust, providing some stability.

Cash Flow

Operating cash flow has been relatively stable, with a slight increase in free cash flow in 2024. The free cash flow to net income ratio indicates a stronger cash position relative to earnings, despite negative net income. However, consistent negative net income presents a risk to sustainable cash flow generation.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.79B	3.96B	3.92B	4.25B	3.34B
	Gross Profit
1.96B	2.09B	2.13B	2.36B	1.66B
	EBIT
-879.00M	-85.00M	306.00M	622.00M	456.00M
	EBITDA
-532.00M	232.00M	-677.00M	972.00M	336.00M
	Net Income Common Stockholders
-910.00M	-132.00M	-950.00M	411.00M	-83.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
272.00M	334.00M	365.00M	339.00M	438.00M
	Total Assets
5.75B	7.37B	7.64B	9.22B	9.34B
	Total Debt
2.27B	2.30B	2.09B	2.24B	2.41B
	Net Debt
2.00B	1.97B	1.73B	1.90B	1.97B
	Total Liabilities
3.81B	4.08B	3.83B	4.18B	4.37B
	Stockholders Equity
1.94B	3.29B	3.81B	5.04B	4.97B
Cash Flow		Free Cash Flow
281.00M	228.00M	368.00M	515.00M	548.00M
	Operating Cash Flow
461.00M	377.00M	517.00M	657.00M	635.00M
	Investing Cash Flow
-197.00M	-89.00M	-138.00M	-358.00M	-1.11B
	Financing Cash Flow
-302.00M	-307.00M	-329.00M	-379.00M	490.00M

DENTSPLY SIRONA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15.94
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Neutral. The current price of 15.94 is below the 20-day moving average (MA) of 16.20, above the 50-day MA of 14.70, and below the 200-day MA of 18.98, indicating a neutral trend. The MACD of 0.30 indicates Positive momentum. The RSI at 53.79 is Neutral, neither overbought nor oversold. The STOCH value of 47.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XRAY.

DENTSPLY SIRONA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	85 Outperform	$36.61B	28.03	25.81%	0.84%	9.54%	37.23%
HOLX	70 Outperform	$14.05B	27.16	11.77%	―	1.66%	21.95%
COO	69 Neutral	$14.20B	35.08	5.15%	―	6.88%	21.11%
BDX	68 Neutral	$49.02B	32.64	5.97%	2.33%	5.84%	15.12%
XRAY	58 Neutral	$3.17B	―	-34.47%	4.03%	-5.61%	-921.99%
BAX	57 Neutral	$15.47B	136.07	-8.96%	2.65%	-20.17%	-138.32%
Sector *	54 Neutral	$5.24B	3.27	-45.39%	2.80%	16.77%	-0.07%

DENTSPLY SIRONA Corporate Events

Dentsply Sirona Announces $550 Million Notes Offering

On June 5, 2025, Dentsply Sirona Inc. announced it had entered into an Underwriting Agreement with Goldman Sachs & Co. LLC to issue and sell $550 million of its 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055. The net proceeds of approximately $544.5 million from this offering will be used for general corporate purposes, including repaying existing indebtedness. The offering is expected to close on June 12, 2025, subject to customary closing conditions, and is part of the company’s strategy to manage its financial obligations effectively.

The most recent analyst rating on (XRAY) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Amends Credit Facility for Flexibility

On June 3, 2025, DENTSPLY SIRONA Inc. secured consent from its lenders to amend its revolving credit facility and entered into several agreements to adjust financial covenants and debt management strategies. These amendments, including a new financial covenant and leverage ratio adjustments, aim to enhance financial flexibility and manage interest rate risks, potentially impacting the company’s financial operations and stakeholder interests.

The most recent analyst rating on (XRAY) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

Dentsply Sirona Appoints New CFO Matthew E. Garth

On May 27, 2025, Dentsply Sirona announced the appointment of Matthew E. Garth as Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of financial management experience, having previously served in senior roles at The Scotts Miracle-Gro Company and Minerals Technologies Inc. His appointment is seen as a strategic move to drive Dentsply Sirona’s transformational journey and enhance shareholder value, with a focus on advancing the company’s financial, operational, and strategic goals.

The most recent analyst rating on (XRAY) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Holds Annual Stockholder Meeting

On May 21, 2025, DENTSPLY SIRONA held its annual meeting of stockholders where several key decisions were made. These included the election of eleven directors, the ratification of Deloitte and Touche LLP as the company’s independent accountants for 2025, approval of executive compensation for 2024, and an amendment to increase shares under the 2024 Omnibus Incentive Plan. These decisions reflect the company’s ongoing governance and strategic planning efforts.

The most recent analyst rating on (XRAY) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

Dentsply Sirona CEO Takes on Interim CFO Role

On May 8, 2025, Dentsply Sirona announced that Herman V. Cueto completed his role as interim CFO, with CEO Simon D. Campion temporarily assuming the financial officer duties. The company reported a 7.7% decrease in net sales for Q1 2025 compared to the previous year, impacted by foreign currency changes and a decline in Byte sales. Despite these challenges, Dentsply Sirona maintained its outlook for organic sales and adjusted EPS, emphasizing its commitment to long-term performance through transformational initiatives.